←
Reshma Ramachandran7,363 posts
Reshma Ramachandran avatar

Reshma Ramachandran

@reshmagar

@YaleMed Assistant Prof, @Yale_CRRIT Co-Director, @Drsforamerica Board of Directors #patientsbeforeprofits *Views here are my own*

◷ Joined April 2010▧ 782 Photos and videos
Reshma Ramachandran avatar
Reshma Ramachandran@reshmagar·8 Dec 2025

While this paper focuses on FAERS (FDA's passive drug safety surveillance system), the limitations also apply to VAERS for vaccines. Current FDA leadership is using VAERS to make conclusions despite its many limitations & with no transparency of how the reports were investigated.

Now out in @NEJM is a new Perspective piece from the CRRIT team on the potential consequences of @US_FDA’s recent announcement to release daily drug adverse event reports from FDA’s Adverse Event Reporting System (FAERS) nejm.org/doi/full/10.1056/NE… (1/10)

Larry Levitt avatar
⟳ Reshma Ramachandran retweeted
Larry Levitt@larry_levitt·Nov 12

When people retire at 65 and shift from employer health insurance to Medicare, health spending decreases substantially because prices in Medicare are much lower than in private insurance.

Post attachment
Reshma Ramachandran avatar
Reshma Ramachandran@reshmagar·Oct 29

The winners of yesterday's HHS ill-advised policy to seemingly legitimize unproven peptides with no clinical evidence of safety, efficacy, & quality aren't patients but telehealth platforms & compounders (for Hims, they're one & the same), now gifted a peptide-laden cash cow.

Today you can get a first look at Peptides+, our new specialty built around a clinically guided protocol and ongoing clinical support. We’ve been building for this. Join the list to be among the first in line when we launch: hims.com/peptides-plus Important disclaimers here: news.hims.com/disclaimers/ca…

Reshma Ramachandran avatar
Reshma Ramachandran@reshmagar·Oct 29

Also, the "safety measures" included in this policy will do very little to protect patients. Lats week, I explained why: x.com/reshmagar/status/21134… As @CSPI's Peter Lurie said: "They’re trying to create the appearance of guardrails where none exist." (h/t @MargaretManto)

A plan to give people in the U.S. easier access to unproven peptide drugs favored by Health Secretary Robert F. Kennedy Jr. was opposed by most FDA scientific staff members, who had limited input in drafting the policy, according to six people familiar with its development. to.pbs.org/4BBDu6M

Reshma Ramachandran avatar
Reshma Ramachandran@reshmagar·Oct 29

Many thanks to @AP_FDAwriter for making clear that HHS (RFK Jr.) unprecedently went over FDA's technical experts to push this policy forward despite their repeated concerns about the lack of evidence for peptides' safety, efficacy, & quality in patients.

A plan to give people in the U.S. easier access to unproven peptide drugs favored by Health Secretary Robert F. Kennedy Jr. was opposed by most FDA scientific staff members, who had limited input in drafting the policy, according to six people familiar with its development. to.pbs.org/4BBDu6M

ProPublica avatar
⟳ Reshma Ramachandran retweeted
ProPublica@propublica·Oct 29

New: A top U.S. official endorsed a key policy change on hormone replacement therapies while holding at least $115,000 in stock in a company that provides access to menopause treatments. Ethics experts called it an “obvious conflict of interest.” propub.li/4suYw2B

Reshma Ramachandran avatar
Reshma Ramachandran@reshmagar·Oct 28

How can patients give informed consent for a treatment if the telehealth platform & clinician is financially incentivized to prescribe these products of unknown quality, safety, & efficacy? When has a "trust me, bro" policy ever worked for the public jamanetwork.com/journals/jam…

Reshma Ramachandran avatar
Reshma Ramachandran@reshmagar·Oct 28

Hims & Hers acquired its own peptide manufacturing facility in 2025 & is now celebrating this policy allowing unproven peptides as its latest cash grab. As we found in our secret shopper study, there'll be little to no prescriber oversight to protect patients & prevent harms.

$HIMS 🚨 HHS INTERIM ENFORCEMENT PEPTIDE POLICY "The Secretary of HHS [RFK Jr.] has determined that this limited enforcement-discretion policy will discourage the continued, widespread use of certain research-use-only peptides supplied by foreign manufacturers that pose a safety risk to US patients. By allowing limited compounding of the substances addressed in this guidance under appropriate safeguards, the policy provides patients with a more controlled alternative." "Based on the available evidence, including the recommendations of a recent Pharmacy Compounding Advisory Committee, the Secretary has determined that the policy advances patient choice and freedom while appropriately protecting patient safety." "Until a peptide bulk drug substance is addressed in a final rule as being included or not included on the 503A bulks list, HHS does not intend to take action against a State-licensed pharmacy, Federal facility, or licensed physician compounding a drug product using a peptide bulk drug substance that is not a component of an FDA-approved drug product, the subject of an applicable USP or NF monograph, or on the 503A bulks list codified at 21 CFR 216.23(a), when all of the following circumstances are present:" 1. 503A Interim Access List: BPC-157, TB-500, MOTS-c, KPV, Semax, or Epitalon 2. Peptide Identity: The peptide must meet the identity specifications and administration-route limitations in Appendix B 3. Characterization & Testing: The substance must come from an FDA-registered facility and have a valid Certificate of Analysis (COA) confirming identity, purity, potency, and contaminant testing 4. Manufacturer Requirements: The original manufacturer must be FDA-registered, comply with CGMP requirements, and be identified on the COA. Intermediaries must validate suppliers 5. Reporting Requirements: Compounders must report products compounded, serious adverse events, and product quality issues to FDA and relevant states. Reporting instructions must appear on product labeling 6. Product Labeling: Labels must state: “This is a compounded drug product. Not for resale.” 7. Single Active Ingredient: Each compounded product may contain only one peptide API from Appendix A. No peptide combinations. 8. Oral Bioavailability: Oral formulations require documentation demonstrating adequate human bioavailability. 9. Drug Delivery Devices: Only FDA 510(k)-cleared syringes may be packaged with or contain the compounded drug. 10. Compliance With Existing Law: Products must satisfy other applicable FD&C Act requirements, including sanitary compounding conditions and valid patient-specific prescriptions.

Post attachmentPost attachmentPost attachment
Matthew Perrone avatar
⟳ Reshma Ramachandran retweeted
Matthew Perrone@AP_FDAwriter·Oct 28

“This is a wink and nod to the MAHA faithful in the hope that they'll show up at the polls,” said Dr. Peter Lurie, a former FDA official who now leads @CSPI. apnews.com/article/peptides-…

SCOOP: A Trump administration plan to give Americans easier access to unproven peptides was opposed by FDA drug staffers, who had limited input in drafting the policy. apnews.com/article/peptides-…

Reshma Ramachandran avatar
Reshma Ramachandran@reshmagar·Oct 28

Just bonkers after FDA's own scientists concluded that there is no demonstrable evidence of safety, efficacy, or even quality for peptides considered in July for legal compounding. Instead of demanding evidence, HHS essentially says "good luck" to patients in figuring this out.

The key take-away, as expected:

Post attachment
Reshma Ramachandran avatar
Reshma Ramachandran@reshmagar·Oct 23

advice on the benefits and risks of peptides. Instead, patients will rely on the claims from telehealth platforms or businesses benefitting from the sale of peptides. If peptide compounders are so sure of the medical claims, why not just do a robust trial and seek FDA approval?

Reshma Ramachandran avatar
Reshma Ramachandran@reshmagar·Oct 23

For an administration that is so concerned about fraud, waste, and abuse, opening the doors to unproven peptides only creates more of these problems for patients. Plus stripping health insurance from millions means they won't be able to see a doctor who can provide independent...

Reshma Ramachandran avatar
Reshma Ramachandran@reshmagar·Oct 23

in their recommendation to not allow for legal compounding of these peptides (in addition to pointing to decades of evidence showing no demonstrated efficacy or safety nor there being established quality standards for these products): healthaffairs.org/content/fo…

Reshma Ramachandran avatar
Reshma Ramachandran@reshmagar·Oct 23

6. Also, recall that peptide compounders are already marketing (and seeking compounding approval) for specific medical conditions for which effective FDA approved medical treatments exist (and are usually not available on a telehealth website). FDA's own scientists noted this...